Published in Mol Psychiatry on January 01, 2004
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol (2011) 2.43
Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet (2005) 1.85
Role of erythropoietin in the brain. Crit Rev Oncol Hematol (2007) 1.50
Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry (2010) 1.36
Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics (2009) 1.36
Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology (2008) 1.32
TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci U S A (2008) 1.17
Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol (2008) 1.14
Erythropoietin: a multimodal neuroprotective agent. Exp Transl Stroke Med (2009) 1.14
A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain. Proc Natl Acad Sci U S A (2005) 1.03
Systemic adeno-associated virus-mediated gene therapy preserves retinal ganglion cells and visual function in DBA/2J glaucomatous mice. Hum Gene Ther (2011) 1.02
Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci U S A (2009) 0.99
Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res (2007) 0.97
Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives. Front Cell Neurosci (2013) 0.91
Erythropoietin: still on the neuroprotection road. Ther Adv Neurol Disord (2012) 0.90
Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl) (2011) 0.89
Apoptosis induced by parasitic diseases. Parasit Vectors (2010) 0.88
Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice. Neuropsychopharmacology (2010) 0.87
Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med (2012) 0.85
Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice. BMC Biol (2011) 0.85
A new mouse model for mania shares genetic correlates with human bipolar disorder. PLoS One (2012) 0.83
Widespread expression of erythropoietin receptor in brain and its induction by injury. Mol Med (2015) 0.83
Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis. Ther Adv Neurol Disord (2008) 0.82
Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia. Mol Med (2012) 0.81
Erythropoietin has no effect on hippocampal response during memory retrieval 3 days post-administration. Psychopharmacology (Berl) (2007) 0.81
Comparison of Neurite Outgrowth Induced by Erythropoietin (EPO) and Carbamylated Erythropoietin (CEPO) in Hippocampal Neural Progenitor Cells. Korean J Physiol Pharmacol (2012) 0.79
Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. Mov Disord (2011) 0.79
Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model. Psychopharmacology (Berl) (2010) 0.78
Revisiting adult neurogenesis and the role of erythropoietin for neuronal and oligodendroglial differentiation in the hippocampus. Mol Psychiatry (2016) 0.78
In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography. Eur Radiol (2014) 0.76
Activated platelets in carotid artery thrombosis in mice can be selectively targeted with a radiolabeled single-chain antibody. PLoS One (2011) 0.75
Discovery of a master regulator of injury and healing: tipping the outcome from damage toward repair. Mol Med (2014) 0.75
Prolyl-4-hydroxylase 2 and 3 coregulate murine erythropoietin in brain pericytes. Blood (2016) 0.75
Perioperative erythropoietin protects the CNS against ischemic lesions in patients after open heart surgery. Wien Klin Wochenschr (2016) 0.75
Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A (1986) 15.20
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42
Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature (1986) 11.09
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol (2000) 9.73
The biology of cachectin/TNF--a primary mediator of the host response. Annu Rev Immunol (1989) 9.63
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science (1986) 9.19
Cachectin: more than a tumor necrosis factor. N Engl J Med (1987) 8.74
Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med (1985) 8.18
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 7.96
fw2.2: a quantitative trait locus key to the evolution of tomato fruit size. Science (2000) 7.91
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature (1985) 7.22
Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med (1988) 7.22
Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med (1994) 7.19
Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med (1976) 7.02
TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet (1990) 6.32
Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem (1988) 5.75
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol (1985) 5.38
MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 5.21
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A (2000) 5.20
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med (1988) 5.16
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (1985) 4.98
Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 4.59
Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A (1984) 4.04
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med (1994) 3.95
Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci U S A (1989) 3.88
Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry (2008) 3.85
Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med (1991) 3.81
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A (2001) 3.80
Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med (1981) 3.70
Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A (1982) 3.69
Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol (1993) 3.68
Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J (1989) 3.67
Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature (1992) 3.67
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol (1992) 3.57
The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today (1988) 3.40
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science (1986) 3.36
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro. Proc Natl Acad Sci U S A (1971) 3.27
Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science (1981) 3.25
Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med (1984) 3.14
Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokinetic properties. J Exp Med (1988) 3.06
Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem (1992) 3.06
Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain (2008) 3.05
Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. Mol Biochem Parasitol (1980) 3.05
Mind reading: neural mechanisms of theory of mind and self-perspective. Neuroimage (2001) 3.03
Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc Natl Acad Sci U S A (1990) 3.01
Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest (1991) 3.00
Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science (1985) 2.94
Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain (2000) 2.90
The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis. J Exp Med (1990) 2.89
Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain (2008) 2.83
Cachectin/tumour necrosis factor. Lancet (1989) 2.77
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 2.71
Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol (1988) 2.66
Macrophage inflammatory protein 1 modulates macrophage function. J Immunol (1992) 2.66
Distal venous arterialisation for salvage of critically ischaemic inoperable limbs. Lancet (1999) 2.64
Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care (1997) 2.63
Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med (2008) 2.55
Protein glycation, diabetes, and aging. Recent Prog Horm Res (2001) 2.51
Cloning and characterization of cDNAs for murine macrophage inflammatory protein 2 and its human homologues. J Exp Med (1990) 2.44
Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol (1996) 2.41
Cloning of a novel family of mammalian GTP-binding proteins (RagA, RagBs, RagB1) with remote similarity to the Ras-related GTPases. J Biol Chem (1995) 2.41
Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol (1989) 2.41
Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ (2004) 2.39
The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. Biochem J (2001) 2.36
An iron-carboxylate bond links the heme units of malaria pigment. Proc Natl Acad Sci U S A (1991) 2.36
Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med (1991) 2.32
Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care (1997) 2.32
Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype. J Exp Med (1986) 2.28
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med (2001) 2.27
Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci U S A (1984) 2.26
Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett (1985) 2.23
Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med (1989) 2.21
Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol (1985) 2.21
The EPIC nutrient database project (ENDB): a first attempt to standardize nutrient databases across the 10 European countries participating in the EPIC study. Eur J Clin Nutr (2007) 2.21
Structure of carbohydrate of hemoglobin AIc. J Biol Chem (1977) 2.21
Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci U S A (1992) 2.20
Neural correlates of first-person perspective as one constituent of human self-consciousness. J Cogn Neurosci (2004) 2.16
The Hamilton scales and the Hopkins Symptom Checklist (SCL-90). A cross-national validity study in patients with panic disorders. Br J Psychiatry (1992) 2.16
Lipopolysaccharide-treated RAW 264.7 cells produce a mediator that inhibits lipoprotein lipase in 3T3-L1 cells. J Immunol (1985) 2.15
Diabetic cataract formation: potential role of glycosylation of lens crystallins. Proc Natl Acad Sci U S A (1978) 2.14
High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci U S A (1985) 2.11
Net costs of dementia by disease stage. Acta Psychiatr Scand (2011) 2.11
Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A (1997) 2.10
Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A (1992) 2.09
Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.09
The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest (1990) 2.08
The identification of leaf thionin as one of the main jasmonate-induced proteins of barley (Hordeum vulgare). Plant Mol Biol (1992) 2.08
Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry (2008) 2.07
An analysis of the saccadic system by means of double step stimuli. Vision Res (1979) 2.07
Specificity determinants of substrate recognition by the protein kinase DYRK1A. J Biol Chem (2000) 2.05